Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies.

@article{Schatz2011TargetingTP,
  title={Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies.},
  author={Jonathan H Schatz},
  journal={Current oncology reports},
  year={2011},
  volume={13 5},
  pages={
          398-406
        }
}
Signaling by the PI3K/AKT/mTOR pathway is frequently deregulated in non-Hodgkin's lymphoma (NHL), prompting evaluation of the rapamycin-analog (rapalog) mTOR inhibitors in multiple clinical trials. The drugs show activity as single agents, and the rapalog temsirolimus is now accepted as a therapeutic option in relapsed/refractory mantle cell lymphoma. Response rates, however, are typically below 50%, resulting in remissions that are neither complete nor durable. Results of preclinical studies… CONTINUE READING
BETA
Highly Cited
This paper has 37 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 52 REFERENCES

beyond PI3K and PTEN

  • TD Bunney, Katan M. Phosphoinositide signalling in cancer
  • Nat Rev Cancer. ;10(5):342–52. 404 Curr Oncol…
  • 2011
2 Excerpts

Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4 EBPeIF 4 E

  • AC Hsieh, M Costa, O Zollo
  • Cancer Cell
  • 2010

Similar Papers

Loading similar papers…